3.4.4. LV Systolic Dysfunction and Symptomatic HF 
±
Only one patient in the control group (4%) and none in the ivabradine group had a decrease in LVEF < 50%. The mean baseline LVEF was 63.5 ± 3.4% in the ivabradine and 64.4 ± 4.5% in the control group (Symptomatic CTRCD was diagnosed in one patient from the control group when HF symptoms appeared, and reduced LVEF (31%) was determined after four cycles of anthracyclines. After guideline-based HF therapy [